Exelixis (EXEL) Azione Prezzo
Exelixis Prezzo
Negli ultimi 19 anni Exelixis ha aumentato il fatturato del 18,1% all'anno, raggiungendo 2,32 miliardi USD. L'utile per azione è cresciuto del 11,8% all'anno negli ultimi 14 anni. Per Exelixis, il margine netto del 33,7% risulta in aumento rispetto al 16,1% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per Exelixis è 52,00 USD, circa il 24,6% sotto il prezzo attuale di mercato. Su 24 analisti, 11 valutano il titolo come acquisto — nel complesso un consenso Mantenere.
Exelixis Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Exelixis Azione e analisi azionaria
Domande frequenti sull'azione Exelixis
The business model of Exelixis Inc is focused on the development, commercialization, and discovery of therapies for the treatment of cancer. The company primarily engages in the research and development of small molecule therapies, targeting specific pathways that contribute to the growth and spread of cancer cells. Exelixis Inc aims to bring innovative and effective cancer treatments to patients by leveraging its expertise in drug discovery and development. The company collaborates with various partners, including pharmaceutical companies and research institutions, to advance its pipeline of potential oncology treatments.
Exelixis Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Exelixis Inc in the market are Bristol-Myers Squibb Co., Merck & Co. Inc., and Pfizer Inc.
Exelixis Inc. is a biotechnology company founded in 1994, headquartered in Alameda, California. The company focuses on the discovery, development, and commercialization of novel therapies to treat cancer and other serious diseases. With a strong emphasis on precision medicine, Exelixis aims to improve patients' lives through targeted therapies. Throughout its history, Exelixis has made significant advancements in drug development and has brought several innovative medicines to market. Notably, the company's flagship product, CABOMETYX® (cabozantinib), has been approved for the treatment of various cancers. Exelixis continues to invest in research and development, collaborating with partners to expand its pipeline and deliver new treatments to patients worldwide.
Exelixis Inc, a renowned biotechnology company, has achieved significant milestones in its journey. Notably, the company secured a major breakthrough with the FDA approval of its flagship product, Cabometyx, for the treatment of advanced renal cell carcinoma. Additionally, Exelixis Inc successfully expanded Cabometyx's indications to include advanced hepatocellular carcinoma, solid tumors, and differentiated thyroid cancer. The company also witnessed positive clinical trial results, demonstrating the efficacy of Cabometyx in several cancer types. Exelixis Inc's continuous dedication to research and development has propelled it to become a leading name in the pharmaceutical industry, revolutionizing cancer treatment with groundbreaking therapies.
Exelixis Inc is primarily present in the United States, focusing on developing and commercializing innovative medicines. Based in Alameda, California, the company's operations extend across the nation. Exelixis Inc has established strategic partnerships and collaborations worldwide, engaging in research and development efforts with renowned institutions and organizations globally.
Exelixis Inc represents values of innovation, collaboration, and commitment to improving patients' lives. With a focus on discovering and developing small molecule drugs, the company strives for scientific excellence in bringing groundbreaking therapies to market. Exelixis Inc is dedicated to advancing the field of oncology with their portfolio of targeted medicines, addressing the unmet needs of cancer patients. By fostering partnerships and working closely with the medical community, Exelixis Inc believes in the power of collaboration to drive meaningful progress in the fight against cancer.
Gli analisti fissano attualmente un prezzo obiettivo medio di 51,78 USD per l’azione Exelixis (mediana: 52,00 USD), pari a -25,0 % rispetto all’ultimo prezzo. Il consenso si basa su 24 giudizi di analisti.
24 analisti valutano attualmente l’azione Exelixis: 11 raccomandano l’acquisto, 12 la tenuta e 1 la vendita. Per il 2026 gli analisti si aspettano per Exelixis ricavi pari a 2,56 miliardi USD e un utile per azione di 3,75 USD.
Convertita al tasso di cambio attuale, l’azione Exelixis quota 62,56 EUR (69,00 USD).
L’azione Exelixis (EXEL) è quotata su 8 borse, tra cui: NASDAQ (EXEL), London (0IJO.L), SIX (Zürich) (EX9.SW), XETRA (EX9.DE), Frankfurt (EX9.F), München (EX9.MU), Düsseldorf (EX9.DU).
Exelixis Inc. is a biopharmaceutical company specializing in the research, development, and marketing of drugs for the treatment of cancer. The company is headquartered in Alameda, California, USA. The business model of Exelixis is based on three pillars: research and development, product marketing and licensing, and collaborations and partnerships with other pharmaceutical companies. Research and development involve the discovery of new compounds and therapies for the treatment of cancer. Exelixis specializes in identifying signaling pathways that are important for the survival and growth of tumor cells. The company has an extensive pipeline of cancer drugs in various stages of development. The most well-known product of Exelixis is Cabozantinib, which is approved for the treatment of kidney cancer and thyroid cancer. Exelixis markets its products through its own sales organization in the USA and through partnerships with other companies worldwide. The company aims to expand its presence in the USA and other countries to increase revenue and profits. Exelixis also works closely with other pharmaceutical companies to acquire licenses for new technologies and products, and to form partnerships for the joint development and marketing of drugs. These collaborations can help accelerate Exelixis' research and development efforts and bring its products to market faster. In summary, the business model of Exelixis Inc. is based on the research, development, and marketing of cancer drugs. The company engages in extensive research and development, has a pipeline of drugs in various stages of development, and collaborates with other companies to acquire new technologies and products and form partnerships for the joint development and marketing of drugs. Exelixis aims to expand its presence in the US and international markets to increase its revenue and profit.
Il attesa fatturato di Exelixis ammonta a 2,56 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Exelixis ammonta a 1,06 miliardi USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Exelixis è attualmente 18,39. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Exelixis.
Il rapporto prezzo/fatturato (P/S) di Exelixis è attualmente 7,61. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Exelixis.
Il Quality Score AlleAktien per Exelixis è 8/10.
L'ISIN di Exelixis è US30161Q1040. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Exelixis è 936718. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Exelixis è EXEL. Con questo simbolo di borsa vengono negoziate le azioni Exelixis in borsa.
Azione Exelixis
Gruppo di pari di Exelixis
Exelixis Ticker
Exelixis FIGI
Altre metriche e analisi di Exelixis in Deep Dive.
La nostra analisi azionaria dell'azione Exelixis include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Exelixis. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: